title: Interleukin-1 signaling in mouse astrocytes involves Akt: a study with interleukin-4 and IL-10.
abstract: Although astrocytes are well known to respond to the pro-inflammatory cytokine, interleukin-1 (IL-1), the receptor and post-receptor mechanisms that mediate IL-1 effects in this cell type are complex and need further investigation. Using electrophoretic mobility shift assay (EMSA), we show that IL-1beta-induced NFkappaB activation in primary culture of mouse astrocytes is mediated by the interaction of this cytokine with the IL-1 type I receptor/IL-1 receptor accessory protein complex, as demonstrated by the ability of blocking monoclonal antibodies against these receptors to attenuate NFkappaB activation. In addition to NFkappaB activation, IL-1beta is also able to phosphorylate Akt, as demonstrated by Western blot. The observation that addition of wortmanin, that specifically blocks Akt phosphorylation, also attenuates NFkappaB activation can be interpreted that Akt phosphorylation interacts with IL-1 signaling pathways. Furthermore, anti-inflammatory cytokines such as IL-4 and IL-10 that block IL-1b-induced NFkappaB activation also attenuate IL-1beta-induced Akt phosphorylation, despite the fact that IL-4 and IL-10 in isolation induced Akt phosphorylation. All these findings point to an interaction between Akt and NFkappaB-dependent IL-1 signaling in the primary culture of astrocytes.
authors.affiliation: INSERM U. 394, 1, rue Camille-Saint-Saens, 33077 Bordeaux Cedex, France.
authors.forename: F
authors.initials: F
authors.lastname: Pousset
authors.forename: R
authors.initials: R
authors.lastname: Dantzer
authors.forename: K W
authors.initials: KW
authors.lastname: Kelley
authors.forename: P
authors.initials: P
authors.lastname: Parnet
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D001253:Astrocytes / Q000187:drug effects / Q000276:immunology / Q000502:physiology*; D001921:Brain / Q000166:cytology / Q000276:immunology; D002478:Cells, Cultured; D007375:Interleukin-1 / Q000494:pharmacology*; D016753:Interleukin-10 / Q000494:pharmacology*; D015847:Interleukin-4 / Q000494:pharmacology*; D051379:Mice; D016328:NF-kappa B / Q000378:metabolism; D051058:Oncogene Protein v-akt; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D010766:Phosphorylation; D017472:Receptors, Interleukin-1 / Q000235:genetics* / Q000502:physiology; D015682:Retroviridae Proteins, Oncogenic / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D015398:Signal Transduction / Q000187:drug effects / Q000276:immunology / Q000502:physiology*
chemical_list: D007375:Interleukin-1; D016328:NF-kappa B; D017472:Receptors, Interleukin-1; D015682:Retroviridae Proteins, Oncogenic; D016753:Interleukin-10; D015847:Interleukin-4; D019869:Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt